Department of Pharmacy, Indiana University Health West Hospital, Avon, IN.
Department of Pharmacy, Indiana University Health Methodist Hospital, Indianapolis, IN.
Am J Health Syst Pharm. 2020 Jun 23;77(13):1051-1053. doi: 10.1093/ajhp/zxaa114.
Piperacillin/tazobactam is a broad-spectrum antibiotic that is widely used and commonly administered via the intravenous (i.v.) piggyback route over 0.5 to 4.0 hours. Recommendations for i.v. push (IVP) administration of piperacillin/tazobactam are lacking due to the high osmolality of the solution. The primary objective of this study was to retrospectively assess the safety and tolerability of piperacillin/tazobactam administered peripherally by IVP. Methods. A retrospective chart review was conducted to evaluate adverse drug reactions after administration of a single dose of IVP piperacillin/tazobactam through a peripheral line in an emergency department from August 2016 through November 2017.
A total of 1,813 patients received 1 dose of IVP piperacillin/tazobactam during the study timeframe. Three hundred patients were randomly selected for assessment of safety and tolerability. Two hundred ninety-nine patients (99.7%) tolerated IVP piperacillin/tazobactam. One patient had an allergic reaction that included itching and hives. No infusion-related reactions were documented.
IVP administration of piperacillin/tazobactam through a peripheral site is safe and tolerable for adult patients.
哌拉西林/他唑巴坦是一种广谱抗生素，广泛应用于临床，通常通过静脉（i.v.）输液袋以 0.5 至 4.0 小时的时间给药。由于该溶液的渗透压较高，因此缺乏关于哌拉西林/他唑巴坦静脉推注（IVP）给药的建议。本研究的主要目的是回顾性评估通过外周静脉途径 IVP 给药的哌拉西林/他唑巴坦的安全性和耐受性。方法。回顾性病历审查评估了 2016 年 8 月至 2017 年 11 月期间在急诊科通过外周静脉通路单次给予 IVP 哌拉西林/他唑巴坦后发生的药物不良反应。结果。在研究期间，共有 1813 例患者接受了 1 剂 IVP 哌拉西林/他唑巴坦治疗。随机选择 300 例患者评估安全性和耐受性。299 例（99.7%）患者耐受 IVP 哌拉西林/他唑巴坦。1 例患者发生过敏反应，包括瘙痒和荨麻疹。未记录到与输注相关的反应。结论。对于成年患者，通过外周部位 IVP 给予哌拉西林/他唑巴坦是安全且耐受良好的。
